OIS at AAO 2015

Aura Biosciences

Nov 12, 2015 11:25am ‐ Nov 12, 2015 11:33am


Description

Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.

Speaker(s):

You must be logged in and own this session in order to post comments.